The Cancer Institute Hospital

A study to learn how well HER3-DXd (patritumab deruxtecan) works and how safe it is in people with previously treated non-small-cell lung cancer that has a mutation in the EGFR gene: a plain language summary of the HERTHENA-Lung01 study

Plain Language SummaryWhat is this summary about?This is a summary of the publication about the HERTHENA-Lung01 study, which was published in the Journal of Clinical Oncology in September 2023. The study included 277 adults with non-small-cell lung cancer (NSCLC) that had a mutat...

Treatment Outcomes for Gastric Cancer With Positive Peritoneal Lavage Cytology or Localized Peritoneal Metastasis

Importance In the era of modern systemic chemotherapy, the optimal treatment strategy for gastric cancer with positive peritoneal lavage cytology (CY1) and/or localized peritoneal metastasis (P1a) remains controversial. Objective To explore the optimal treatment strategy for pati...

Survival Results by the Prospectively Determined Clinical Staging for Locally Advanced Gastric Cancer: A Follow‐Up Study of JCOG1302A

ABSTRACT Background Long‐term overall survival (OS) of gastric cancer stratified by the prospectively determined clinical stage remains unclear. Methods This is an ancillary study of JCOG1302A, a prospective observational study that evaluated the accuracy of clinical diagnosis of...

Real-world event-free survival with neoadjuvant pembrolizumab plus chemotherapy and adjuvant pembrolizumab in early-stage triple-negative and estrogen receptor-low, HER2-negative breast cancer

Neoadjuvant pembrolizumab plus chemotherapy and adjuvant pembrolizumab has become a standard treatment for patients with early-stage triple-negative breast cancer (TNBC) based on the KEYNOTE-522 trial; however, real-world data on event-free survival (EFS) remain limited. We aimed...

Lymphovascular invasion and nodal positivity may identify candidates for adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma

OBJECTIVE: To identify patients with high-risk muscle-invasive urothelial carcinoma (MIUC) who derive greater benefit from adjuvant nivolumab after radical surgery. PATIENTS AND METHODS: This single-center retrospective study included 246 patients with high-risk MIUC who underwen...

Tarlatamab in small cell lung cancer following platinum-based chemotherapy: subgroup analysis of Japanese patients from the DeLLphi-304 study

Abstract Background In the Phase 3 DeLLphi-304 trial, tarlatamab significantly improved overall survival (OS) over chemotherapy for small-cell lung cancer (SCLC) progressed after platinum-based chemotherapy. We report efficacy and safety in the Japanese subpopulation. Methods Pat...

Inverted urothelial papilloma: Diagnostic challenges, molecular insights, and clinical implications.

mutations, challenging the long-held assumption that these cells are morphologically and genetically normal. Future studies should investigate whether similar genetic alterations in morphologically normal urothelium occur in other urothelial tumors. This could refine understandin...

De-escalation of perioperative systemic therapy for early breast cancer.

Breast cancer is the most common malignancy among women worldwide, and the number of survivors continues to increase owing to earlier detection and advances in treatment. As long-term survivorship becomes increasingly important, minimizing treatment-related toxicity without compr...

Real-world safety and effectiveness of olaparib maintenance after first-relapse platinum-sensitive ovarian cancer in Japan: a multicenter historical cohort (JGOG3026)

OBJECTIVE: The primary objective of the study was to evaluate the safety and effectiveness of olaparib maintenance therapy in Japanese patients with platinum-sensitive first-relapsed ovarian cancer. The secondary objective was to survey the treatment given after the olaparib main...